Last $55.05 USD
Change Today -0.69 / -1.24%
Volume 182.5K
ANIP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

ani pharmaceuticals inc (ANIP) Snapshot

Open
$56.64
Previous Close
$55.74
Day High
$56.64
Day Low
$54.22
52 Week High
11/18/14 - $56.99
52 Week Low
12/4/13 - $12.81
Market Cap
623.7M
Average Volume 10 Days
320.1K
EPS TTM
$1.07
Shares Outstanding
11.3M
EX-Date
--
P/E TM
51.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANI PHARMACEUTICALS INC (ANIP)

Related News

No related news articles were found.

ani pharmaceuticals inc (ANIP) Related Businessweek News

No Related Businessweek News Found

ani pharmaceuticals inc (ANIP) Details

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company offers generic products, including Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema for the treatment of ulcerative colitis; Metoclopramide syrup for treating heartburn symptoms with gastroesophageal reflux disease; and Opium Tincture to treat severe diarrhea by slowing the movement of the intestines, as well as branded products, such as Cortenema and Reglan tablets. It also provides contract manufacturing for various branded and generic companies. The company markets its products through wholesalers, retail market chains, distributors and mail order pharmacies, and hospitals. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

81 Employees
Last Reported Date: 02/28/14

ani pharmaceuticals inc (ANIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.5K
Chief Financial Officer, Vice President and S...
Total Annual Compensation: $233.6K
Vice President of Operations
Total Annual Compensation: $131.4K
Vice President of New Business Development & ...
Total Annual Compensation: $91.4K
Vice President of Quality & Product Developme...
Total Annual Compensation: $112.6K
Compensation as of Fiscal Year 2013.

ani pharmaceuticals inc (ANIP) Key Developments

ANI Pharmaceuticals, Inc. Announces the Launch of Methazolamide Tablets USP

ANI Pharmaceuticals, Inc. announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.

ANI Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014; to Launch Vancocin in Fourth Quarter of 2014

ANI Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenues of was $17,387,000 against $7,836,000 a year ago. The increase in Revenue was due to a 135% increase in net prescription sales from $6.4 million to $15.0 million, primarily as a result of sales of ANI's newly acquired products, Lithobid and Vancocin, as well as price increases for the company's existing products. Operating income was $8,199,000 against $810,000 a year ago. Income before income tax was $8,291,000 against $958,000 a year ago. Diluted earnings per share was $0.59 against $0.13 a year ago. Net income from continuing operations was $6,746,000 against $1,041,000 a year ago. Net income was $6,746,000 against $1,191,000 a year ago. Adjusted EBITDA was $10,078,000 against $1,696,000 a year ago. Adjusted net income was $7,438,000 or $0.66 per diluted share. The company generated $4.2 million of positive cash flows from operations. For the nine months, the company reported net revenues of was $34,933,000 against $19,550,000 a year ago. The increase in Revenue was due to a 111% increase in net prescription sales from $13.8 million to $29.2 million, primarily as a result of increased existing product sales, as well as sales of ANI's newly acquired products, Lithobid and Vancocin. Contract sales, development services, and royalty revenues were $5.7 million, consistent with the prior year period. Operating income was $9,234,000 against loss of $2,562,000 a year ago. Income before income tax was $9,319,000 against loss before tax of $3,365,000 a year ago. Net income from continuing operations was $7,742,000 against net loss from continuing operations of $3,282,000 a year ago. Net income was $7,742,000 against net loss of $3,132,000 a year ago. Diluted earnings per share was $0.59 against $0.13 a year ago. Adjusted EBITDA was $14,549,000 against $3,582,000 a year ago. The company generated $11.3 million of positive cash flows from operations. The company expects to launch Vancocin under its own label in the fourth quarter. The company announced the guidance for the fourth quarter of 2014 is based on management's current estimates of the Company's market share for its products, product pricing, cost of sales, and operating costs. Net revenues estimated to be between $17 million and $18 million. Adjusted non-GAAP EBITDA, excluding non-cash stock compensation expense, estimated to be between $9.75 million and $10.25 million. Adjusted non-GAAP earnings per share, excluding non-cash stock compensation expense, estimated to be between $0.60 and $0.65 per share, assuming 11,318,014 shares outstanding. An estimated effective tax rate of 18%.

ANI Pharmaceuticals Mulls Acquisitions

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) is looking for acquisition opportunities. Arthur S. Przybyl, President and Chief Executive Officer of ANI said, "We continue to advance our internal generic product development efforts while selectively pursuing acquisitions and partnerships for late stage ANDA products and mature brands."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIP:US $55.05 USD -0.69

ANIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Glenmark Pharmaceuticals Ltd 819.40 INR 0.00
View Industry Companies
 

Industry Analysis

ANIP

Industry Average

Valuation ANIP Industry Range
Price/Earnings 52.6x
Price/Sales 13.6x
Price/Book 6.3x
Price/Cash Flow 43.9x
TEV/Sales 12.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANI PHARMACEUTICALS INC, please visit www.anipharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.